What is PRK XTRA?

PRK XTRA is a procedure that combines PRK with a prophylactic treatment using Avedro’s KXL Accelerated Corneal Collagen Cross-Linking with Riboflavin. The cross-linking portion is shorter than for therapeutic treatment. Typically there is a 75 – 90 second Riboflavin soak time and then 75 – 90 seconds of UVA exposure.

What is the recovery like?

The recovery is the same as for PRK. If the epithelium is removed, as in PRK, a bandage contact lens is applied to the eye after the procedure. The patient is monitored until the epithelium has healed back and then the bandage contact lens is removed. The patient is typically on antibiotic and anti-inflammatory drops for about 1 week after surgery, depending on the cornea’s healing response. Patients would return for regular visits to monitor corneal changes and refractive error changes.

How well does it work?

Typically only one treatment is required. The structural strength of the cornea is stronger than you started with. Studies have shown that for about 95% of Keratoconus patients the cross-linking procedure prevents further vision loss.

How long does it last?

Over a decade of results have shown that cross-linking appears to last for a long time and there is evidence that the strengthening effect will be permanent. Corneal Collagen Cross-linking with Riboflavin treatment can be repeated if necessary.

What can it treat?

For therapeutic use, it can treat conditions such as Keratoconus, Forme Fruste Keratoconus (an extremely mild or subclinical form of Keratoconus), Pellucid Marginal Degeneration and post-laser refractive surgery ectasia.

For prophylactic use, virtually any patient can be treated with cross-linking to reduce the chance of future development of the above conditions. Patients with thinner than normal corneas, irregular corneal astigmatism, asymmetry on corneal topography, against-the-rule astigmatism or steeper than normal corneas may especially benefit.

Who qualifies for treatment?

Minimum age of 18; Minimum corneal thickness of 325µm; Those with corneal disease such as Keratoconus, Pellucid Marginal Degeneration or corneal ectasia; Those interested in prophylactic treatment.